Franklin Biotechnology Discovery Fund Class C FBTDX

Medalist Rating as of | See Franklin Templeton Investment Hub
  • NAV / 1-Day Return 177.71  /  −2.27 %
  • Total Assets 1.2B
  • Adj. Expense Ratio
    1.770%
  • Expense Ratio 1.760%
  • Distribution Fee Level Below Average
  • Share Class Type Level Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield 1.38%
  • Turnover 22%

USD | NAV as of Jul 11, 2026 | 1-Day Return as of Jul 11, 2026, 12:11 AM GMT+0

Morningstar’s Analysis FBTDX

Will FBTDX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

A lean team and undifferentiated approach in a complex industry.

Associate Analyst Natalia  Arrigoni

Natalia Arrigoni

Associate Analyst

Summary

Franklin Biotechnology has experienced managers, but limited supporting resources and a sensible yet undistinguished process limit its appeal.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTDX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 38.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Jazz Pharmaceuticals PLC

6.30 67M
Healthcare

Gilead Sciences Inc

4.67 50M
Healthcare

Amgen Inc

4.50 48M
Healthcare

Vertex Pharmaceuticals Inc

4.11 44M
Healthcare

argenx SE ADR

3.85 41M
Healthcare

Regeneron Pharmaceuticals Inc

3.53 38M
Healthcare

Guardant Health Inc

3.04 32M
Healthcare

Revolution Medicines Inc Ordinary Shares

3.00 32M
Healthcare

Ascendis Pharma AS

2.74 29M
Healthcare

Praxis Precision Medicines Inc Ordinary Shares

2.52 27M
Healthcare

Sponsor Center